Cardiac involvement in children with community-acquired pneumonia and respiratory failure
e | 10 set 2020
INFORMAZIONI SU QUESTO ARTICOLO
Article Category: Brief communication (original)
Pubblicato online: 10 set 2020
Pagine: 119 - 124
DOI: https://doi.org/10.1515/abm-2020-0018
Parole chiave
© 2020 Kachaporn Nimdet et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Effects of cardiac involvement to length of hospital stay
| ST/T changes | 14.62 ± 16.74 | 10.68 ± 7.59 | 0.115 |
| Arrhythmia | 8.00 ± 2.94 | 12.65 ± 13.20 | 0.355 |
| Pericardial effusion | 12.06 ± 6.42 | 13.12 ± 19.11 | 0.702 |
| Valvular regurgitation | 15.67 ± 23.39 | 11.55 ± 7.46 | 0.122 |
| Myocardial injury | 13.99 ± 15.06 | 10.04 ± 7.61 | 0.082 |
Echocardiographic measurments at first and second echocardiography
| Valvular regurgitation | 30 (22%) | 2 (2%) | 0.046 |
| Pericardial effusion | 80 (59%) | 13 (9%) | 0.002 |
| Pericardial effusion (mm) | 1.28 ± 1.09 | 0.17 ± 0.48 | 0.002 |
| IVSs (mm) | 9.17 ± 1.60 | 9.11 ± 1.61 | 0.780 |
| IVSd (mm) | 7.61 ± 1.40 | 7.49 ± 1.36 | 0.420 |
| LVPWD (mm) | 7.97 ± 1.65 | 7.84 ± 1.39 | 0.430 |
| LVDD (mm) | 24.97 ± 4.17 | 24.46 ± 4.70 | 0.130 |
| LVEF (%) | 70.99 ± 9.56 | 73.26 ± 11.26 | 0.040 |
| LVIMP | 0.46 ± 0.08 | 0.40 ± 0.05 | <0.001 |
| RVIMP | 0.36 ± 0.09 | 0.30 ± 0.04 | <0.001 |
| RVSP (mmHg) | 30.05 ± 5.97 | 24.91 ± 2.54 | <0.001 |
Baseline characteristics of study population
| Age (months) | 13.58 ± 9.81 (2–50) |
| Male | 73 (54%) |
| Body mass index (kg/m2) | 17.88 ± 2.83 (11.7–30.5) |
| Peak of fever (celcius) | 39.13 ± 0.74 (35.8–41) |
| Duration of fever before admission (days) | 3.64 ± 1.80 (2–11) |
| Total duration of fever (days) | 7.99 ± 4.28 (4–28) |
| Intubation period (days) | 5.29 ± 4.67 (1–40) |
| Length of hospital stay (days) | 12.47 ± 12.83 (4–128) |
| Type of infections | |
| Bacteria | 54 (40%) |
| Virus | 74 (55%) |
| Culture negative | 7 (5%) |
| Hemoglobin (g/dL) | 10.95 ± 1.38 (7.5–14.3) |
| Hematocrit (%) | 32.80 ± 5.32 (24.1–42.1) |
| White blood count (cells/cu mm) | 15516.56 ± 6649.06 (4570–37400) |
| Blood urea nitrogen (mmol/L) | 9.72 ± 4.41 (3–23.5) |
| Creatinine (mg/dl) | 0.33 ± 0.10 (0.1–0.7) |
| Aspartate aminotransferase (IU/L) | 56.63 ± 62.52 (5–615) |
| Alanine transaminase (IU/L) | 42.92 ± 98.98 (7–691) |
| Albumin (g/dL) | 4.18 ± 0.43 (2.5–5.2) |
Cardiac laboratory measurements at admission date and second investigation date
| CXR: Cardiothoracic ratio | 0.51 ± 0.04 | 0.48 ± 0.03 | <0.001 |
| Electrocardiogram | |||
| Heart rate | 146.34 ± 18.98 | 123.49 ± 19.23 | <0.001 |
| ST/T changes | 66 (49%) | 9 (7%) | 0.035 |
| Arrhythmia | 7 (5%) | 4 (3%) | <0.001 |
| Myocardial injury | 83 (62%) | 16 (12%) | 0.047 |
| Troponin T (ng/mL) | 0.04 ± 0.05 | 0.01 ± 0.02 | <0.001 |